Research programme: sustained-release diabetes/obesity therapeutics - Amylin/Pacira BioSciences
Latest Information Update: 15 Apr 2019
Price :
$50 *
At a glance
- Originator Amylin Pharmaceuticals; Pacira Pharmaceuticals
- Class Peptides; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus; Obesity
Most Recent Events
- 09 Apr 2019 Pacira Pharmaceuticals is now called Pacira Biosciences
- 03 May 2012 No development reported - Preclinical for Diabetes mellitus in USA (SC)
- 03 May 2012 No development reported - Preclinical for Obesity in USA (SC)